CD274 and neoplasm: It first received FDA approval on 13 November 2020 as combination therapy with chemotherapy for patients with unresectable locally-advanced or metastatic TNBC whose tumours have a PD-L1 CPS ≥ 10 based on the Dako 22C3 assay[10].